دورية أكاديمية
Clinical Investigation of Efficacy of Pemetrexed in 32 Patients with Pulmonary Adenocarcinoma after Failure to Chemotherapy and Gefitinib
| العنوان: | Clinical Investigation of Efficacy of Pemetrexed in 32 Patients with Pulmonary Adenocarcinoma after Failure to Chemotherapy and Gefitinib |
|---|---|
| المؤلفون: | Biao WU, Cheng HUANG, Kan JIANG, Wu ZHUANG, Zhenwu XU, Jing ZHANG |
| المصدر: | Chinese Journal of Lung Cancer, Vol 13, Iss 8, Pp 809-812 (2010) |
| بيانات النشر: | Chinese Anti-Cancer Association; Chinese Antituberculosis Association, 2010. |
| سنة النشر: | 2010 |
| المجموعة: | LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| مصطلحات موضوعية: | Pemetrexed, Lung neoplasms, Chemotherapy, Gefitinib, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| الوصف: | Background and objective The relapse-free time of gefitinib as the second or third line therapy in patients with advanced non-small cell lung cancer (NSCLC) was not satisfactory. The aim of this study is to evaluate the efficacy and toxicity of pemetrexed in patients with pulmonary adenocarcinoma after failure to chemotherapy and gefitinib. Methods A total of 32 relapsed patients with pulmonary adenocarcinoma after failure to chemotherapy and gefitinib received pemetrexed 500 mg/m2 by the intravenous administration on the first day, with 21 days as a cycle. Dexamethasone, folic acid and vitamin B12 were applied to relieve the drug toxicity. The objective response rate was estimated by Response Evaluation Criteria in Solid Tumors (RECIST) and the toxicity was estimated by National Cancer Institute Common Toxicity Criteria (version 3.0). Results For a total of 32 patients, 4 patients reached partial response (PR), constituting a total of 12.5%; 11 patients reached stable disease (SD), constituting a total of 34.4%; 17 patients reached progressive disease (PD), constituting a total of 53.1%. The median progression free survival (PFS) was 2.7 months. The median overall survival (OS) was 11.0 months. One-year survival rate was 37.5%. The most common adverse events (AEs) were myelosuppression with grade I and grade II toxicity. Other adverse events were tolerated. Conclusion Pemetrexed was clinically beneficial for the patients with pulmonary adenocarcinoma after the failure of chemotherapy and gefitinib. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | Chinese |
| تدمد: | 1009-3419 1999-6187 |
| العلاقة: | http://www.lungca.org/index.php?journal=01&page=article&op=viewFile&pathTest[]=10.3779%2Fj.issn.1009-3419.2010.08.11&path[]=1649; https://doaj.org/toc/1009-3419Test; https://doaj.org/toc/1999-6187Test |
| الوصول الحر: | https://doaj.org/article/a4954ea2b0b54ea1bcc43a65f45e8058Test |
| رقم الانضمام: | edsdoj.4954ea2b0b54ea1bcc43a65f45e8058 |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 10093419 19996187 |
|---|